Across TCGA pan-cancer cohorts, KRT18P50 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of KRT18P50’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where KRT18P50 RNA is repressed in tumor relative to normal tissue. In most cancer types KRT18P50 is over-expressed in tumor, although a few such as KIRC and ESCA show the opposite, repressed pattern.

KIRC, THCA, and ESCA are the cancer types where KRT18P50 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in KRT18P50 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	All	−0.021	<.001	6	view →
THCA	All	II,III,IV	+0.016	.012	2	view →
ESCA	All	All	−0.158	.027	1	view →
KIRP	All	All	−0.032	.006	1	view →
KICH	All	All	−0.012	.017	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: KRT18P50 RNA expression & survival · all KRT18P50 data types